Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H23NO3.C10H16O4S |
Molecular Weight | 545.687 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CCOC3=C4O[C@H]5[C@@H](O)C=C[C@H]6[C@H]7CC(C=C3)=C4[C@@]56CCN7C
InChI
InChIKey=NKOFCJOTATYGHA-LAZTUONISA-N
InChI=1S/C19H23NO3.C10H16O4S/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h4-7,12-14,18,21H,3,8-10H2,1-2H3;7H,3-6H2,1-2H3,(H,12,13,14)/t12-,13+,14-,18-,19-;7-,10-/m01/s1
Molecular Formula | C10H16O4S |
Molecular Weight | 232.297 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C19H23NO3 |
Molecular Weight | 313.3908 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
CNS Activity
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
222 μM × min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
8.5 mg single, oral |
healthy, 10 months |
Other AEs: Sedation... |
1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
Other AEs: Dizziness, Drowsiness... Other AEs: Dizziness (7 patients) Sources: Drowsiness (slight, 2 patients) Loose stools (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sedation | grade 5 | 8.5 mg single, oral |
healthy, 10 months |
Loose stools | 1 patient | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
Dizziness | 7 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
Drowsiness | slight, 2 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
PubMed
Title | Date | PubMed |
---|---|---|
Acute renal failure due to concomitant action of methotrexate and indomethacin. | 1986 Jun 14 |
|
Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse. | 2003 Oct |
|
Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors. | 2003 Sep |
|
Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives. | 2005 Jul 8 |
|
Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry. | 2005 Jun |
|
Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood. | 2008 May |
|
Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry. | 2009 Apr 15 |
|
Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays. | 2009 May |
|
[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value]. | 2009 Nov 4-12 |
Sample Use Guides
The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:39:01 GMT 2025
by
admin
on
Mon Mar 31 23:39:01 GMT 2025
|
Record UNII |
RX4SJ3L382
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RX4SJ3L382
Created by
admin on Mon Mar 31 23:39:01 GMT 2025 , Edited by admin on Mon Mar 31 23:39:01 GMT 2025
|
PRIMARY | |||
|
279-118-1
Created by
admin on Mon Mar 31 23:39:01 GMT 2025 , Edited by admin on Mon Mar 31 23:39:01 GMT 2025
|
PRIMARY | |||
|
91808966
Created by
admin on Mon Mar 31 23:39:01 GMT 2025 , Edited by admin on Mon Mar 31 23:39:01 GMT 2025
|
PRIMARY | |||
|
100000088240
Created by
admin on Mon Mar 31 23:39:01 GMT 2025 , Edited by admin on Mon Mar 31 23:39:01 GMT 2025
|
PRIMARY | |||
|
79241-89-7
Created by
admin on Mon Mar 31 23:39:01 GMT 2025 , Edited by admin on Mon Mar 31 23:39:01 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|